Treatment of Children With Insufficient Secretion of Growth Hormone

Learn more about:
Related Clinical Trial
Assessment of Adherence, Quality of Life, Clinical Response and Safety of Daily and Long-Acting Growth Hormone Therapy Impact of GH Measurements on GHD Diagnosis Fluids Administration During Combined Clonidine-Arginine Growth Hormone Stimulation Test Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™ The Impact of the Use of Recombinant Human Growth Hormone on ADHD Characteristics in Children and Adolescents Constructing an Insulin-Like Growth Factor-based Prediction Model Peripheral Metabolic Effects of Somatostatin Chromosome 18 Clinical Research Center The Effect of Dietary Fat Load and Physical Exercise on the Flexibility and Partitioning of Ectopic Lipids. An Observational Study on Treatment Compliance by Children Treated With Growth Hormone A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacodynamics of Long Acting Growth Hormone A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy Subjects Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese Growth Hormone as Add-on Treatment in Severe Fibromyalgia With Low IGF-1 Serum Levels (56 Characters) A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood Safety and Efficacy of Long-term Somatropin Treatment in Adults Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial Effects of Growth Hormone and IGF-1 on Anabolic Signals and Stem Cell Recruitment in Human Skeletal Muscle Genotropin Study Assessing Use of Injection Pen Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary Validation of a Questionnaire That Identifies the Reasons for Non-adherence to Existing Growth Hormone Therapy Treatment of Children With Insufficient Secretion of Growth Hormone Metabolic and QOL Effects of GH Treatment in Patients With TBI and AGHD Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA) Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children Inter-Assay Growth Hormone and IGF-I Variability A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device Cardiovascular Risk in Growth Hormone Deficient Young Adult Males After Completing Growth Hormone Therapy Easypod United States User Trial National Cooperative Growth Study in CKD Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients Practicability and Acceptability of Stylomax® in Children Growth Hormone’s Effect on the Cardiovascular System Exploring Interactions Between Growth Hormone and the Microbiome Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children Phase 1 Safety Study of ALRN-5281 in Healthy Subjects Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients Growth Hormone and Chromosome 18q- and Abnormal Growth An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin® Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood Study of TV-1106 in Growth Hormone-Deficient Adults Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children Long-Term Efficacy and Safety of Growth Hormone Replacement Therapy in Chronic Heart Failure Crossover Study to Assess the Safety and Pharmacokinetic of Pegylated Somatropin(PEG Somatropin) in GHD Children Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates Gene Expression in Monocytes of Growth Hormone Deficient Children Study of Pituitary Size and Function in Familial Dwarfism of Sindh Adipocyte Function and Somtropin Deficiency Sustained Release Formulation of Somatropin (rDNA Origin)for Injection Molecular Basis of the Growth Axis in Short Stature Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States The Effects of Growth Hormone (GH) on Lipid Depots The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients Reference Values for Body Composition Parameters and IGF-I in the Adult NordiNet® International Outcome Study Effects of Growth Hormone Supplementation to Adults With Growth Hormone Deficient on Metabolism and Adipose Tissue Molecular Phenotype Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing Metabolic Endocrinology and Growth Hormone in Adults Growth Hormone Treatment of Young Growth Hormone-Deficient Adults Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.) rhGH Therapy on Hepatic Drug Metabolism Skeletal Muscle Effects of GH in Boys Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas Adipose Tissue and Serum Inflammation in GH Deficiency Adipose Tissue and Circulating Markers of Inflammation in GH Deficiency and Changes With GH Therapy

Brief Title

Treatment of Children With Insufficient Secretion of Growth Hormone

Official Title

A Phase III, Multi-centre, Randomised, Parallel Group Study of Safety and Efficacy of the LB03002 a New Sustained Release Formulation of Human Recombinant Growth Hormone as Compared to Standard Daily Therapy in Treatment Naive Children With Growth Failure Due to Insufficient Secretion of Endogenous Growth Hormone

Brief Summary

      The purpose of this study is to compare a new weekly administered growth hormone preparation
      with standard daily treatment in children with insufficient secretion of growth hormone

Detailed Description

      Treatment with recombinant human growth hormone (somatropin) has been proven to be effective
      in stimulating height velocity and improving height in children with short stature due to
      insufficient endogenous Growth Hormone secretion. Currently somatropin is available in daily
      injection formulations. The requirement of daily administration causes significant burden and
      interruption of normal daily life. A product with less frequent dosing regimen will provide
      considerable improvement over currently available conventional replacement therapy regimens.

      The primary objective of this study is to demonstrate the clinical comparability in terms of
      safety and efficacy of a new sustained release recombinant human growth hormone formulation
      to that of daily growth hormone.

Study Phase

Phase 3

Study Type


Primary Outcome

Height velocity at the end of 12 months treatment

Secondary Outcome

 1.Height velocity SD score (HV SDS) after 12 months treatment, 2.Serum IGF-I levels3. Serum IGFBP-3 levels


Growth Hormone Deficiency (GHD)


growth hormone (somatropin)

Study Arms / Comparison Groups

 LB03002, sustained release human hGH
Description:  LB03002


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

September 2005

Primary Completion Date

December 2013

Eligibility Criteria

        Inclusion Criteria:

          -  Pre-pubertal children (boys age: > 3 and <12 years or girls: age >3 and <11 years)
             with isolated GH insufficiency, GH insufficiency as part of multiple pituitary hormone
             deficiencies, or organic GH insufficiency. If GH insufficiency occurred after
             treatment for any brain tumour, the patient has to be at least one year in clinical
             remission which has to be confirmed by computer tomography (CT) or magnetic resonance
             imaging (MRI) scan (with contrast) within 3 months prior to study entry

          -  Children with negative signs for intracranial tumour or tumour growth as confirmed
             with a CT or MRI scan (with contrast) within 12 months prior to inclusion or at
             inclusion visit

          -  Confirmed diagnosis of GH insufficiency as determined by two different GH provocation
             tests, defined as a peak plasma GH level of ≤7 ng/ml

          -  No prior exposure to rhGH therapy (GH-treatment naive)

          -  Height (HT), except in children suffering from organic GH insufficiency, of at least
             2.0 standard deviations (SD) (HT SDS £-2.0) below the mean height for chronological
             age (CA) and sex according to the 2000 standards from the Centers for Disease Control
             and Prevention (CDC).

          -  Height velocity (HV) of at least 1 SD (HV SDS £-1) below the mean HV for CA and sex
             according to the standards of Prader. The minimum time between two standard height
             measurements should be at least 6 month before inclusion.

          -  Baseline IGF-I level of at least 0.5 SD (IGF-1 SDS£-0.5) below the mean IGF-1 level
             standardised for age and sex according to the central laboratory reference values.

          -  Written informed consent of parent or legal guardian of subject.

        Exclusion Criteria:

          -  Any clinically significant abnormality likely to affect growth or the ability to
             evaluate growth, such as, but not limited to, chronic diseases like renal
             insufficiency, spinal cord irradiation, and malnutrition (BMI must be above -2SD and
             below +2SD of mean BMI for the chronological age and sex according to the CDC
             standards, and albumin must be above lower limit of normal (LLN) of the central
             laboratory for a patient to be included).

          -  Patients with overt diabetes mellitus (Fasting blood sugar >126 mg/dl) and impaired
             fasting sugar (Fasting blood sugar >100 mg/dl after repeated blood analysis)

          -  Chromosomal abnormalities and medical "syndromes" (Turner's syndrome, Laron syndrome,
             Noonan syndrome or absence of growth hormone receptors), with the exception of
             septo-optic dysplasia

          -  Congenital abnormalities (causing skeletal abnormalities), Russell-Silver Syndrome,
             skeletal dysplasias

          -  Closed epiphyses

          -  Other growth promoting medication such as anabolic steroids, with the exception of
             pituitary hormone replacement therapy, thyroxine, hydrocortisone and desmopressin
             (DDAVP) replacement therapies

          -  Children requiring glucocorticoid therapy (e.g. asthma) that are on the dose of more
             than 400 µg/d of inhaled budesonide or equivalents inhaled for longer than 1 month
             during a calendar year

          -  Bone age (BA) higher than chronological age

          -  Poorly controlled or uncontrolled pituitary insufficiencies of other axes (e.g.,
             thyroid-stimulating hormone, adrenocorticotropic hormone/cortisol, vasopressin
             deficiency): Children who are on stable replacement therapy for less than 6 months for
             thyroid replacement therapy, and less than 3 months for other hormonal deficiencies
             prior to enrolment

          -  Major medical conditions and/or presence of contraindication to rhGH treatment

          -  Known or suspected HIV-positive patient or patient with advanced diseases such as AIDS
             or tuberculosis

          -  Drug, substance, or alcohol abuse

          -  Known hypersensitivity to the components of study medication

          -  Evidence of tumour growth or malignant disease

          -  Presence of anti-hGH antibodies at screening

          -  The patient and/or the parent/legal guardian are likely to be non-compliant in respect
             to study conduct.




3 Years - 11 Years

Accepts Healthy Volunteers



, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Study Sponsor

LG Life Sciences


 BioPartners GmbH

Study Sponsor

, , 

Verification Date

March 2010